---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-033064"
form_type: "8-K"
ticker: "AXSM"
cik: "0001579428"
company_name: "Axsome Therapeutics, Inc."
filed_at: "2025-03-05T23:59:59+00:00"
generated_at: "2026-05-25T10:22:53.540620+00:00"
event_type: "litigation"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Axsome settles Sunosi patent litigation with Hikma; generic entry deferred to 2040

## Summary
- Settlement with Hikma resolves patent litigation over Sunosi (solriamfetol) generic.
- License for Hikma's generic Sunosi begins Sept 1, 2040 (with pediatric exclusivity) or March 1, 2040 (without).
- Agreement subject to FTC/DOJ review; other patent litigation against other parties remains pending.
- Axsome retains exclusive Sunosi rights until at least 2040, protecting key product revenue.

## SEC filing metadata
- accession: 0000950170-25-033064
- form_type: 8-K
- ticker: AXSM
- cik: 0001579428
- company_name: Axsome Therapeutics, Inc.
- filed_at: 2025-03-05T23:59:59+00:00
- event_type: litigation
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1579428/000095017025033064/0000950170-25-033064-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1579428/000095017025033064/axsm-20250305.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-033064
- JSON: https://secwatch.observer/filing/0000950170-25-033064.json
- Plain text: https://secwatch.observer/filing/0000950170-25-033064.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.